T1	Participants 56 121	older adolescents and young adults with autism spectrum disorders
T2	Participants 406 594	20 older adolescents and young adults with autism spectrum disorders using two dosing strategies (50 mg daily versus 50 mg weekly) for 8 weeks with a 2-week follow-up after discontinuation
